Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이용현 | * |
dc.date.accessioned | 2022-08-12T16:31:31Z | - |
dc.date.available | 2022-08-12T16:31:31Z | - |
dc.date.issued | 2022 | * |
dc.identifier.issn | 2093-5552 | * |
dc.identifier.other | OAK-32041 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/262462 | - |
dc.description.abstract | Background: Currently nanomedicines are the focus of attention from researchers and clinicians because of the successes of lipid-nanoparticles-based COVID-19 vaccines. Nanoparticles improve existing treatments by providing a number of advantages including protection of cargo molecules from external stresses, delivery of drugs to target tissues, and sustained drug release. To prevent premature release-related side effects, stable drug loading in nanoformulations is required, but the increased stability of the formulation could also lead to a poor drug-release profile at the target sites. Thus, researchers have exploited differences in a range of properties (e.g., enzyme levels, pH, levels of reduced glutathione, and reactive oxygen species) between non-target and target sites for site-specific release of drugs. Among these environmental stimuli, pH gradients have been widely used to design novel, responsive nanoparticles. Area covered: In this review, we assess drug delivery based on pH-responsive nanoparticles at the levels of tissues (tumor microenvironment, pH ~ 6.5) and of intracellular compartments (endosome and lysosome, pH 4.5–6.5). Upon exposure to these pH stimuli, pH-responsive nanoparticles respond with physicochemical changes to their material structure and surface characteristics. These changes include swelling, dissociation, or surface charge switching, in a manner that favors drug release at the target site (the tumor microenvironment region and the cytosol followed by endosomal escape) rather than the surrounding tissues. Expert opinion: Lastly, we consider the challenges involved in the development of pH-responsive nanomedicines. © 2022, The Author(s) under exclusive licence to The Korean Society of Pharmaceutical Sciences and Technology. | * |
dc.language | English | * |
dc.publisher | Springer | * |
dc.subject | Endosomal escape | * |
dc.subject | Nanomedicines | * |
dc.subject | pH-responsiveness | * |
dc.subject | Tumor microenvironment | * |
dc.title | Smart pH-responsive nanomedicines for disease therapy | * |
dc.type | Review | * |
dc.relation.issue | 4 | * |
dc.relation.volume | 52 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 427 | * |
dc.relation.lastpage | 441 | * |
dc.relation.journaltitle | Journal of Pharmaceutical Investigation | * |
dc.identifier.doi | 10.1007/s40005-022-00573-z | * |
dc.identifier.scopusid | 2-s2.0-85129772864 | * |
dc.author.google | Shinn J. | * |
dc.author.google | Kwon N. | * |
dc.author.google | Lee S.A. | * |
dc.author.google | Lee Y. | * |
dc.contributor.scopusid | 이용현(38561637800) | * |
dc.date.modifydate | 20231214111942 | * |